Circadian Variation of Plasminogen-Activator-Inhibitor-1 Levels in Children with Meningococcal Sepsis

PLoS One. 2016 Nov 28;11(11):e0167004. doi: 10.1371/journal.pone.0167004. eCollection 2016.

Abstract

Objective: To study whether the circadian variation of plasminogen-activator-inhibitor-1 (PAI-1) levels, with high morning levels, is associated with poor outcome of children with meningococcal sepsis presenting in the morning hours.

Design: Retrospective analysis of prospectively collected clinical and laboratory data.

Setting: Single center study at Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands.

Subjects: 184 patients aged 3 weeks to 18 years with meningococcal sepsis. In 36 of these children, PAI-1 levels at admission to the PICU were measured in plasma by ELISA.

Interventions: None.

Measurements and main results: Circadian variation was studied by dividing one day in blocks of 6 hours. Patients admitted between 6:00 am and 12:00 am had increased illness severity scores and higher PAI-1 levels (n = 9, median 6912 ng/mL, IQR 5808-15600) compared to patients admitted at night (P = 0.019, n = 9, median 3546 ng/mL, IQR 1668-6118) or in the afternoon (P = 0.007, n = 7, median 4224 ng/mL, IQR 1804-5790). In 184 patients, analysis of circadian variation in relation to outcome showed more deaths, amputations and need for skin grafts in patients admitted to the PICU between 6:00 am and 12:00 am than patients admitted during the rest of the day (P = 0.009).

Conclusions: Circadian variation of PAI-1 levels is present in children with meningococcal sepsis and is associated with illness severity, with a peak level in the morning. Whether circadian variation is an independent risk factor for morbidity and mortality in meningococcal sepsis needs to be explored in future studies.

MeSH terms

  • Adolescent
  • Biomarkers / blood*
  • Child
  • Child, Preschool
  • Circadian Rhythm / physiology*
  • Female
  • Humans
  • Infant
  • Male
  • Meningitis, Meningococcal / blood
  • Meningitis, Meningococcal / complications
  • Meningitis, Meningococcal / diagnosis*
  • Neisseria meningitidis / isolation & purification
  • Plasminogen Activator Inhibitor 1 / blood*
  • Prospective Studies
  • Retrospective Studies
  • Sepsis / blood
  • Sepsis / diagnosis*
  • Sepsis / microbiology

Substances

  • Biomarkers
  • Plasminogen Activator Inhibitor 1
  • SERPINE1 protein, human

Grants and funding

Research leading to these results has received funding from the European Union’s seventh Framework program under EC-GA no. 279185 (EUCLIDS). Also, research has been supported, in part, by an unrestricted grant from Baxter Bioscience, Vienna, Austria, in 2000. We declare that the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.